Physician profile
Donald A Sharp
NPI 1780652230
$3,906.01
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $1,071 · 2021: $1,399 · 2022: $22.96.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $991.13 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $788.18 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $358.31 | 2019-2022 | |
| Genentech USA, INC. | $241.89 | 2019-2021 | |
| Janssen Biotech, INC. | $207.27 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $194.59 | 2019-2021 | |
| Pfizer INC. | $125.20 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $117.89 | 2019-2020 | |
| Genzyme Corporation | $116.52 | 2019-2021 | |
| Ucb, INC. | $115.46 | 2020-2021 | |
| Lilly USA, LLC | $111.11 | 2019-2021 | |
| Celgene Corporation | $100.91 | 2019 | |
| Amgen INC. | $98.26 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $66.50 | 2020-2021 | |
| Dusa Pharmaceuticals, INC. | $60.70 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $47.27 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.18 | 2019 | |
| Smith+Nephew, INC. | $17.89 | 2019 | |
| Dermira, INC. | $17.41 | 2019 | |
| Strata Skin Sciences, INC. | $17.24 | 2019 | |
| Incyte Corporation | $14.78 | 2021 | |
| Organogenesis INC. | $13.90 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $13.42 | 2019 | |
| Nabriva Therapeutics, Plc | $13.24 | 2021 | |
| Merck Sharp & Dohme LLC | $12.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.